Join to View Full Profile
11 Nevins StSte 303Boston, MA 02135
Phone+1 617-787-8181
Fax+1 617-787-4644
Dr. Staskin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ronald Reagan UCLA Medical CenterUrology, 1984 - 1985
University of Pennsylvania Health SystemResidency, Urology, 1980 - 1984
University of California (San Diego) Medical CenterInternship, Transitional Year, 1979 - 1980
Drexel University College of MedicineClass of 1979
Certifications & Licensure
MA State Medical License 1985 - 2027
NY State Medical License 2002 - 2010
American Board of Urology Urology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Top Doctors: New York Metro Area Castle Connolly, 2005-2009
- Join now to see all
Clinical Trials
- Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US Start of enrollment: 2015 Apr 01
Publications & Presentations
PubMed
- Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, Christian Gratzke, John Heesakkers
World Journal of Urology. 2025-11-03 - Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.Kenneth M Peters, Janet Owens-Grillo, Elizabeth Thomas, David Staskin, Eric S Rovner
Urology. 2025-09-01 - 2 citationsVibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, Christian Gratzke, John Heesakkers
World Journal of Urology. 2025-08-26
Press Mentions
Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingMay 16th, 2022- Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (Vibegron) 75 Mg at 2022 American Urological Association Annual MeetingApril 13th, 2022
- Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (Vibegron) 75 Mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart RateSeptember 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
